INTRODUCTION
Antibiotic pressure, poor infection control practices and the high burden of nosocomial bacteria such as Acinetobacter baumanii, Pseudomonas aeruginosa and Klebsiella pneumoniae have contributed to the ever increasing number of multidrug-resistant (MDR) infections seen among patients admitted to intensive care units (ICU). 1 2 The choice of available antimicrobials to treat patients with these highly resistant isolates is limited, as they are nonsusceptible to at least three major classes of antibiotics-cephalosporins, aminoglycosides, quinolones and carbapenems. 3 In response to the increasing burden of these Gram-negative nosocomial infections, colistin use has increased on a global scale. 2 The formulation available in South Africa is colistin methane-sulfonate (CMS), a pro-drug of colistin which is hydrolysed to the active form of the drug. 4 There is no literature on the pharmacodynamics of colistin in critically ill children. Dosing schedules of colistin in the literature are dependent on the form of colistin used. Colistin base is used at a dose of 2.5-5 mg/kg/day in three or four doses (75 000-150 000 IU/kg). 5 CMS is used with a reported dose range of 25 000-75 000 IU/kg/day in two or three doses, with only one case involving the use of a loading dose mentioned in the literature for paediatrics. [5] [6] [7] CMS in this study was available in the formulation of one vial of 80 mg equivalent to 1 000 000 IU (1 mg=12 500 IU). There is some evidence to suggest that colistin should be used in combination with other antibiotics when treating MDR bacteria. 6 8 Colistin used simultaneously via the intravenous and nebulised routes may be more efficacious for treating ventilator-associated pneumonia. 9 10 Several publications have confirmed the benefit and safety of colistin use in adults with MDR Gram-negative bacteria; but there are limited safety What is already known on this topic ▸ Multiresistant Gram-negative bacteria are significant contributors to morbidity and mortality in paediatric intensive care. ▸ Colistin is frequently prescribed to treat multiresistant Gram-negative bacteria, despite safety concerns. ▸ Colistin leads to bacteriological and clinical resolution in the majority of cases.
What this study adds
▸ This study provides novel information about the use of colistin in HIV-infected infants and children and HIV-exposed infants and children. ▸ HIV-infected children had a poorer clinical and bacteriological response to colistin treatment than HIV-uninfected/unexposed children.
studies in critically ill children. 11 12 Data regarding the use of colistin in HIV-infected patients is scant, with only two adult and no paediatric studies. HIV-infected adults were reported to tolerate colistin well. 13 14 This study aimed to assess the effectiveness and safety of colistin in HIV-infected critically ill children treated for MDR Gram-negative infections.
METHODS Setting
The paediatric ICU (PICU) at Inkosi Albert Luthuli Central Hospital (IALCH) is a multidisciplinary unit in KwaZulu-Natal, South Africa, which serves approximately 3.7 million children under 12 years of age, with medical and surgical conditions. 15 Caring for children infected and affected by HIV in PICU is common in South Africa, with approximately one-third of the admissions to the PICU at Inkosi Albert Central Hospital being HIV infected. 16 These patients often require prolonged ventilation and are consequently susceptible to acquiring nosocomial pathogens. 17 18 An increasing number of MDR Gram-negative bacterial infections, including K pneumoniae, A baumanii and P aeruginosa have been isolated in the PICU, necessitating the use of colistin from September 2009.
Study design and method
The study was a retrospective observational study of a cohort of critically ill children treated with colistin in the PICU between September 2009 and March 2011. The primary endpoints of this study were all-cause ICU mortality and safety in HIV-infected children. Safety was defined as the absence of nephrotoxic or neurotoxic events. Nephrotoxicity was defined as a twofold increase in creatinine from baseline. Prerenal failure was documented on the basis of clinical diagnosis and rising urea/creatinine ratio. Evidence of neurotoxicity included neuromuscular blockade or seizures due to colistin. Secondary endpoints included clinical resolution and bacteriological eradication after treatment with colistin. Clinical assessment was based on the subjective assessment of the attending physician. Composite clinical improvement was noted if two or more of the following parameters improved-septic markers (white cell count, C reactive protein and procalcitonin), ventilatory requirements or clinical assessment. Bacteriological eradication was defined as the absence of the same organism from the same site on routine samples collected on completion of the colistin course. All laboratory tests for colistin sensitivities were carried out in the IALCH laboratory using the automated Vitek 2 system providing breakpoint minimum inhibitory concentration. Although broth microdilution remains the preferred method for susceptibility testing, the Vitek 2 system is considered to be reliable. 19 Approval was obtained from the University of KwaZulu-Natal (UKZN) Biomedical Research Ethics Committee (BREC), and University of Cape Town Human Research Ethics Committee (HREC), as well as institutional and provincial structures.
Patients treated with colistin during the study period were identified using the pharmacy's electronic database and clinical information was extracted onto standardised case report forms. Data were tested for normality using Shapiro-Wilks test and subsequently analysed using non-parametric Mann-Whitney U tests for continuous data, and χ 2 tests (or Yates-corrected χ 2 for cell values <10) for categorical data. A significance level of p <0.05 was chosen.
Analysis was stratified according to HIV status of cases as either HIV infected, HIV exposed but uninfected, HIV unexposed and uninfected or HIV status unknown. Comparison of baseline characteristics between HIV-infected patients and all HIV-uninfected patients revealed no significant difference between the groups. On the basis that HIV-exposed/uninfected infants have an increased risk of severe infections and different outcome, statistical comparisons are therefore presented between HIV-infected patients and HIV-uninfected/unexposed patients. 20 
RESULTS
Twenty-seven patients received 30 courses of colistin over the study period with median (IQR) age 3 (1.3-4.0) months; 14 (51.9%) male. Patients were mainly admitted for the management of pneumonia (n=15, 55.6%); sepsis (n=7, 25.9%) and congenital heart disease (n=7, 25.9%) (table 1). Eight patients were HIV infected (29.6%); six were HIV exposed/uninfected (22.2%) and 11 patients (40.7%) were HIV unexposed/uninfected. Baseline characteristics of the enrolled subjects according to HIV status showed no differences. Of the 10 courses of colistin in eight HIV-infected patients-three courses were in two children who had antiretroviral therapy (ARV) prior to colistin; in three courses in three patients, ARVs were never commenced. In the other three courses, two patients commenced ARVs once Enrolled subjects had a median (IQR) of 6 (5-8) antibiotics prior to starting colistin, and an average of 8 (6-12) antibiotics over their admission period. The most commonly administered antibiotics were piperacillin/tazobactam (n=10, 37%), amikacin (n=9, 33%) and gentamicin (n=9, 33%). Three children (11%) received no antibiotics in the PICU prior to receiving colistin (table 2) . Eighteen courses of colistin were given in combination with another antibiotic/s; two of these were during the second course of colistin. Combined aerosolised and intravenous colistin was used in 8/30 courses, nebulised colistin was used in 6/30 courses.
The most common MDR bacteria cultured for which colistin was prescribed were Acinetobacter species (n=22, 81.5%), P aeruginosa (n=11, 40.7%) and K pneumoniae (n=7, 25.9%). Positive cultures were obtained from tracheal aspirates in 27/27 (100%), blood 19/ 27 (70.4%) and bronchoalveolar lavage in 2/27 (7.4%) children, as well as from other sites. Co-infection with viruses occurred in 10 (37.0%) patients: cytomegalovirus (CMV) in eight (80%), and one case each of adenovirus and respiratory syncytial virus. CMV occurred in 5/8 (62.5%) HIV-infected children vs 1/11 (9.1%) HIV-uninfected/unexposed children (p=0.049).
Colistin was administered for median (IQR) duration 6 (5-7) days. Renal impairment was noted in 7/30 (23.3%) courses of colistin, in seven patients. Six of these patients had prerenal impairment due to the underlying medical condition, fluid restriction and concomitant use of diuretics. The seventh patient had intrinsic renal failure and was on peritoneal dialysis. It was considered unnecessary to adjust the dose or stop colistin in any of these patients. In the case of the child with established renal failure requiring peritoneal dialysis prior to treatment with colistin, renal function remained static pretreatment and post-treatment. This child was extubated while on colistin and bacteriological eradication was confirmed. The child demised a week postcessation of colistin due to her primary diagnosis.
A composite clinical improvement was noted in 16 of the 30 courses of colistin (53.3%). 6/30 courses (20%) had bacteriological improvement with a negative culture post-treatment with colistin, while 7/30 (28.2%) courses cultured a different organism post-treatment. There was no bacteriological improvement in 5/30 courses (16.7%), as all those patients were HIV infected; and in 12/30 (40%) courses no repeat culture results were obtained.
Eleven of the 27 patients died (40.7%), with no difference in outcome between HIV-infected individuals and HIV-uninfected/ unexposed individuals (table 3) .
Comparison of the clinical and laboratory features of survivors and non-survivors revealed no significant differences between strata including organism and site of infection.
Three cases of resistance to colistin were identified. In all cases, the organism was a pan-drug-resistant A baumanii and all had received piperacillin/tazobactam and amikacin prior to treatment with colistin. One of these children died. The survivors were a 5-week-old infant who had received colistin in the neonatal intensive care unit prior to her admission in the PICU, and a 2-week-old neonate with a congenital heart defect and sepsis. The non-survivor was a 4-month-old female patient who was HIV exposed/uninfected, with a CMV-associated bronchopneumonia, who developed acute respiratory distress syndrome and demised while on colistin.
DISCUSSION
The major finding of the study was the confirmation of safety associated with the use of colistin. Several reports on the safety of colistin have been published, with some reporting cases of renal dysfunction, 5 21 22 while others reported neurotoxic, or nephrotoxic adverse events. 5 23 In our study, prerenal impairment was noted in six patients with an equal distribution among the different HIV status categories. No adverse drug reactions were noted in this series of patients which is in keeping with prior studies. It is important, however, to note that to pick up a 1-2% increase in adverse events, a sample size of 5000 patients would be required to consider colistin as safe. 24 Fifty per cent of HIV-infected patients with MDR bacteria treated with colistin had no bacteriological eradication of the treated organism. This was significantly fewer than the HIV-uninfected/unexposed group where all cases showed bacteriological eradication. These results were not substantially affected by adjusting outcomes in terms of subjects or number of colistin courses used. A previous retrospective study of 13 children receiving 19 colistin courses for Gram-negative infections showed a favourable outcome in 84% of courses with colistin resistance developing in two patients. 5 Another case series of children (n=6) treated with colistin documented a 100% cure rate in patients with microbiologically documented infections, although this study was limited by the small sample size. 23 By contrast with the above studies, the finding of only a 53.3% clinical improvement rate in our study is particularly poor. This difference was accentuated in the HIV-infected group in whom there was an improved clinical assessment in only 30%. In the HIV-uninfected/unexposed group there was a clinical improvement in 75% trending towards reported findings. The reasons for the worse clinical and bacteriological outcomes in HIV-infected patients compared to HIV-uninfected/ unexposed patients were not identified in our study, although possible explanations could include host factors, drug-related factors, such as route and drug combination, and environmental factors. Poor metabolism of colistin in the HIV-infected patients, or drug-to-drug interactions given the higher burden of concomitant medications, or the increased susceptibility to acquire new nosocomial pathogens, may all contribute to this increased rate of treatment failure or act as independent confounders. The fact that HIV-infected patients spent an average of 14 days longer in the PICU than HIV-uninfected/unexposed patients, may have contributed to the poorer outcomes or may be a result of poor response to colistin. These risk factors have not been studied previously and require further evaluation. Furthermore, the significance of these isolates in terms of whether they were truly pathogenic or colonisers requires consideration. 25 We suspect these isolates to be truly pathogenic given the clinical context in which they were found, the associated elevated infective markers and the poor associated outcome.
6 23
The mortality of subjects enrolled in this study (40.7%) is higher than other reports. 5 23 Even though a higher treatment failure rate was recorded among HIV-infected cases, the mortality rate was not significantly different between groups of children according to their HIV status-this may relate to the small sample size. Co-infection with CMV was seen in five of the 11 deaths (45.5%), and in three of the 16 survivors (18.8%). While the presence of CMV showed a trend towards increased mortality, the sample size was too small to statistically detect any effect of CMV on mortality. Previous studies in HIV-infected children and HIV-uninfected children with severe pneumonia have identified CMV-associated pneumonia as being common and associated with a poor outcome in children with advanced HIV disease. 26 A final concern was the high rate of isolation of MDR Gram-negative bacterial pathogens from the unit. There are many mechanisms suggested in the development of drug-resistant bacteria.
1 Acinetobacter species is able to resist antibiotics through multiple strategies including enzymatic, non-enzymatic, as well as efflux pumps. Its mechanism of resistance to colistin is as yet unknown. 27 In our study, we noted the extensive use of antibiotics within these critically ill children. Of the three cases of colistin-resistant A baumanii that were identified in this study, one died. It is of concern that a lack of antibiotic stewardship and the heavy burden of opportunistic infections may account for the excessive use of antibiotics, including colistin. This leads to a spiral effect in practice, which may result in further microbial resistance in the PICU. 28 Strategies for the judicial use of antimicrobials are now the standard of care for intensivists working in PICU.
The small sample size of this study precluded multivariate analysis, and may have resulted in a Type 2 error with insufficient power to detect true differences between groups. We are confident of the clinical relevance of the isolates, as sampling within the ICU is only driven by clinical deterioration. However, the predominant source of microbiological diagnosis was the endotracheal aspirate, taken on clinical grounds which may reflect colonisation of the upper respiratory tract and endotracheal tube. 25 In conclusion, it appears that HIV-infected children with MDR bacteria do not have the same clinical and bacteriological improvement in response to colistin use as compared to HIV-unexposed children and HIV-uninfected children. Further studies are warranted to confirm these findings and interrogate the possible causative factors to this poor response. 
